REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Enzyme Or Coenzyme Containing > Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) > Acting On Peptide Bonds (3.4) (e.g., Urokinease, Etc.) > Serene Proteinases (3.4.21) (e.g., Trypsin, Chymotrypsin, Plasmin, Thrombin, Elastase, Kallikrein, Fibrinolysin, Streptokinease, Etc.) Serene Proteinases (3.4.21) (e.g., Trypsin, Chymotrypsin, Plasmin, Thrombin, Elastase, Kallikrein, Fibrinolysin, Streptokinease, Etc.)Serene Proteinases (3.4.21) (e.g., Trypsin, Chymotrypsin, Plasmin, Thrombin, Elastase, Kallikrein, Fibrinolysin, Streptokinease, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.07/26/07 - 20070172472 - Methods and systems for treating injured cardiac tissue Methods and systems are disclosed for treating cardiac tissue by delivering a platelet composition which induces neovascularization in the cardiac tissue. The platelet composition can additionally contain structural materials and/or bioactive agents. ... 07/19/07 - 20070166299 - Treatment for embolic stroke Provided herein are methods and compositions for treating stroke that include contacting a subject suffering from a stroke with (1) an antioxidant; (2) an antioxidant and one or more of (i) a thrombolytic agent, (ii) an NMDA receptor antagonist and (iii) a spin trap agent; or (3) a thrombolytic agent ... 07/19/07 - 20070166298 - Formulations for the rectal administration of thrombolytically-active agents Pharmaceutical formulations in suppository form, containing thrombolytic agents, which are able to penetrate rectal mucous, for the treatment of acute hemorrhoid diseases and/or diseases of thrombotic origin. ... 06/28/07 - 20070148161 - Biopolymer membrane and methods for its preparation A biopolymermembrane in its substantially dry form having a thickness less than about 75 microns, a solvent content less than about 5% by weight of the membrane, a radius of curvature of less than about 5 centimeters, a density greater than about 1 g/cm3, and a maximum pore size of ... 06/28/07 - 20070148160 - Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots It has now been discovered that certain mutant forms of pro-urokinase (“pro-UK”), such as so-called pro-UK mutant “M5” (Lys.sup.300.fwdarw.His)-, perform in the manner of pro-UK in lysing “bad” blood clots (those clots that occlude blood vessels), while sparing hemostatic fibrin in the so-called “good” blood clots (those clots that seal ... 06/28/07 - 20070148159 - Use of crotoxin as an analgesic - cip A method of producing analgesia and enhancing analgesia is disclosed. The method includes administering a beta-neurotoxin that is characterized by its ability to bind to pre- and postsynaptic receptors resulting in the inhibition of neurotransmission. ... 06/21/07 - 20070141043 - Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment ... 06/14/07 - 20070134231 - Method for prolonging activity of autodegradable enzymes and compositions thereof A composition of a long-acting enzyme comprises the enzyme in a formulation comprising a buffer and an additive selected from the group consisting of tranexamic acid, ε-aminocaproic acid, and analogs of L-lysine other than tranexamic acid and ε-aminocaproic acid, combinations thereof, and mixtures thereof. The composition can further comprise another ... 06/07/07 - 20070128182 - Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment ... 05/17/07 - 20070110740 - Composition and methods for tissue preservation The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention. ... 05/10/07 - 20070104706 - Preparation comprising batroxobin for inhibiting local invasion of malignant tumors A preparation for inhibiting local invasion of malignant tumors is provided which comprises batroxobin and therefore can inhibit local invasion of malignant tumors. A preparation for encapsulating malignant tumor tissues is also provided which comprises batroxobin and therefore can cause or promote formation of capsule-like tissue around malignant tumor tissues. ... 05/10/07 - 20070104705 - Thrombin compositions Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisiting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM to 300 mM NaCl, 0-5 ... 05/10/07 - 20070104704 - Erythropoietin receptor peptide formulations and uses The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages ... 02/22/07 - 20070041962 - Method of promoting healing of a tympanic membrane perforation The present invention relates to the use of plasminogen and plasmin as agents for enhancing healing of tympanic membrane perforations or other wounds, and for reducing scars or necrotic tissue forming during wound healing. The invention also relates to a method for screening of compounds which enhance wound healing by ... 02/22/07 - 20070041961 - Ultrasound target vessel occlusion using microbubbles Selective occlusion of a blood vessel is achieved by selectively damaging endothelial cells at a target location in the blood vessel, resulting in the formation of a fibrin clot proximate to the damaged endothelial cells. Additional fibrinogen can then be introduced into the blood vessel if occlusion is not achieved, ... 02/08/07 - 20070031400 - Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical ... 02/01/07 - 20070025979 - Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses The present invention relates to the use of coagulation proteins and complexes thereof with anticoagulation proteins for the lysis of blood clots or other applications affected by accelerated plasmin production. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of ... 01/18/07 - 20070014782 - Systems for enlarging the diameter of an artery or vein The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have ... 01/18/07 - 20070014781 - Methods for using an elastase The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have ... 01/18/07 - 20070014780 - Storage-stable human fibrinogen solutions Methods are provided for the stable storage of ready-to-use, biocompatible human fibrinogen, which despite its concentration, remains available in fluid form, and which will permit long-term rapid and easy processing into a tissue adhesive preparation. Also provided is the sterile, storage-stable aqueous fibrinogen product resulting from the use of the ... 01/11/07 - 20070009506 - Methods for production of recombinant urokinase Highly efficient methods of producing properly folded recombinant urokinase are provided. Denatured recombinant pro-urokinase is refolded by first solubilizing the protein with a chaotroph at high pH, followed by refolding in the presence of reduced concentrations of chaotroph while the pH is slowly reduced. ... 01/04/07 - 20070003539 - Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments. ... 12/21/06 - 20060286088 - Administration of enoxaparin sodium to patients 75 years and older with st-segment elevation myocardial infarction Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin ... 11/16/06 - 20060257391 - Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment ... 11/02/06 - 20060246053 - Pharmaceutical compositions of fibrinolytic agent Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein. ... 11/02/06 - 20060246052 - Means for stabilization of thrombin and compositions The present invention is to provide a means for the stabilization of thrombin and a stabilized thrombin-containing composition having a good reproducibility of the measurement. There are provided a means for the stabilization of thrombin, characterized in that, effective amount(s) of one or more which is/are selected from calcium ion, ... 10/26/06 - 20060239994 - Novel serine protease bssp4 There are provided proteins having the amino acid sequences represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20; proteins having amino acid sequences derived from these amino acid sequences by deletion, substitution or addition of one to several amino acids; and nucleotide sequences ... 10/05/06 - 20060222641 - Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism The present invention relates to a composition and method for preventing or reducing edema, deep vein thrombosis (DVT), and/or pulmonary embolism by administering a combination of a fibrinolytic agent and an antioxidant. The composition is particularly useful for treating individuals prior to or during long term flights or other situations ... 10/05/06 - 20060222640 - New pharmaceutical compositions for treatment of thrombosis The present invention relates to novel pharmaceutical compositions comprising at least one direct thrombin inhibitor and at least one additional active compound selected from the groups consisting of platelet inhibitors, low molecular weight heparins (LMWH) and heparinoids as well as unfractionated heparin, factor Xa inhibitors, combined thrombin/factor Xa inhibitors, fibrinogen ... 10/05/06 - 20060222639 - Wound treatment utilizing collagenase and a phosphotidylcholine organogel The effect of the action of collagenase in treating lesions containing collagen or mixed fibrin clots (e.g., burns or ulcers) is improved by applying collagenase to the wound in combination with an organogel and a phosphotidylcholine, of which lecithin is a readily available source, particularly when the collagenase is first ... 10/05/06 - 20060222638 - Cholesterol biosynthesis pathway modulators and uses thereof An isolated peptide comprising the amino acid sequence of SEQ ID NO: 2, or a variant, derivative and/or fragment thereof having the function of HMGCoA reductase inhibitor, phosphomevalonate inhibitor, reducing the accumulation of cholesterol in the cholesterol biosynthesis pathway and/or reducing the level of serum cholesterol. Also disclosed is a ... 09/21/06 - 20060210552 - Compositions and methods for systemic inhibition of cartilage degradation Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may ... 09/21/06 - 20060210551 - Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for preventing and treating cerebral complications caused by thrombolytic treatment. The invention also relates to treatment of patients suffering from cerebral complications associated with thrombolysis. Further, the invention provides thrombolytic compositions ... 09/21/06 - 20060210550 - Angiogenesis inducer It is intended to provide an angiogenesis inducer comprising fibrin which is safe to a living body. The angiogenesis inducer is characterized by being capable of safely inducing angiogenesis when administered to a living body, which makes it possible to achieve functional regeneration of living tissues or organs suffering from ... 09/14/06 - 20060204490 - Hemostatic compositions containing sterile thrombin The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the ... 09/07/06 - 20060198837 - Coagulation and fibrinolytic cascades modulator A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker. ... 09/07/06 - 20060198836 - Method of treating hit patients with argatroban This invention relates to the improved methods of use of Argatroban in heparin-induced thombocytopenia. ... 08/31/06 - 20060193846 - Carrier with solid fibrinogen and solid thrombin The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N/cm, density of 1-10 mg/cm3, chamber diameter of more than 0.75 ... 08/17/06 - 20060182735 - Thrombin preparations and process for their production The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remove viruses, is described. Before or after the hydrophobic interaction chromatography it is also ... 08/10/06 - 20060177434 - Reduction of adipose tissue A simple search was made on the Internet. There were at least a few hundred entries. The following seem to be the best of the few dozen examined. The first page of each is cited below for identification. ... 07/13/06 - 20060153831 - Antithrombosis enzyme from the snake venom of agkistrodon acutus This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof. ... 06/22/06 - 20060134094 - Fibrin material and method for producing and using the same This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops a tight structure with thin fibers and small pore size suitable for use as an anti-adhesion ... 06/22/06 - 20060134093 - Fibrin cell supports and methods of use thereof The present invention relates to fibrin cell supports for cell cultures formed by the mixture of plasma proteins including fibrinogen and thrombin. The fibrin cell supports are preferably used for preparing a culture of cells such as keratinocytes, recovering the culture in the form of a reconstituted tissue, and transporting ... 06/15/06 - 20060127390 - Enzymatic inactivation of transmissible spongiform encephalopathy agents and dectection there of The invention relates to a method for inactivating transmissible spongiform encephalopathy agents by contact with a subtilisin protease. The invention further relates to detection of any residual transmissible spongiform encephalopathy agents. ... 06/15/06 - 20060127389 - Fused protein with the function of both hemolysis and anticoagulation and use of it This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, ... 05/25/06 - 20060110381 - Hemostatic compositions containing sterile thrombin The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the ... 05/18/06 - 20060104970 - Biological glue based on thrombin-conjugated nanoparticles Thrombin-conjugated nanoparticles, wherein said nanoparticles comprise one or more organic and/or inorganic compounds and process for preparing the same are provided. The thrombin-conjugated nanoparticles are suitable for use in the preparation of fibrin-based biological sealant. ... 04/27/06 - 20060088519 - Malignant tumor-inhibiting preparation comprising des a fibrin A malignant tumor-inhibiting preparation is provided which comprises Des A fibrin and therefore can inhibit the spreading and migration of malignant tumor cells and thereby can inhibit the malignant tumors. ... 04/27/06 - 20060088518 - Stable thrombin composition The stable thrombin composition comprises purified thrombin, human albumin and a neutral salt, the resulting product being stable when stored as a lyophilisate or frozen and is adjusted to a nominal strength of 500 IU of thrombin or more per ml of solution, the human albumin being in a concentration ... 04/20/06 - 20060083734 - Composition and method for repairing nerve damage and enhancing functional recovery of nerve The present invention relates to a fibrin glue composition for repairing a nerve damage, and/or enhancing the functional recovery of a damaged nerve which comprises an effective amount of nerve growth factor and/or nerve repair enhancer, fibrinogen, aprotinin and divalent calcium ions. The invention also relates to a method for ... 04/20/06 - 20060083733 - High-concentration preparation of soluble thrombomodulin In preparing a soluble thrombomodulin solution having a concentration of as high as 10 mg/mL or above, foam-inhibiting effect can be attained by any method selected from among (a) incorporation of a nonionic surfactant, benzyl alcohol or chlorobutanol, (b) application of silicone coating on the inner wall of the vessel ... 03/09/06 - 20060051340 - Hemostatic materials A safe and effective hemostatic material is provided. A hemostatic material comprising as an effective ingredient thrombin and fibrinogen characterized in that a bioabsorbable synthetic nonwoven fabric is used as a supporting material. The use of the hemostatic material of the present invention allows for quick and thorough hemostasis for ... 02/09/06 - 20060029592 - Methods of treating peripheral arterial occlusions A method is provided for the localized intravascular administration of a fibrinolytic metalloproteinase to a human subject in amounts that are both safe and effective to lyse an occluding fibrin-containing blood clot, while also avoiding the neutralizing effects of α2-macroglobulin in the circulating blood. A method is also provided for ... 02/02/06 - 20060024289 - Cleavage of vegf and vegf receptor by wild-type and mutant proteases Disclosed herein are methods for creating and using mutein proteases with altered specificity for the target molecules they cleave. The invention further discloses methods of using wild-type and mutein granzyme B to target VEGFR proteins to treat diseases, such as cancer. Cleaving VEGFR at certain substrate sequences with wild-type and ... 01/05/06 - 20060002918 - Thrombin compositions Compositions comprising thrombin and methods of preparing them are disclosed. The composition may be in the form of an aqueous solution at pH 5.7-7.4 consisiting essentially of 0.1 mg/mL to 5.0 mg/mL thrombin, 2% to 4% (w/v) sucrose, 3.5% to 5% (w/v) mannitol, 50 mM to 300 mM NaCl, 0-5 ... 12/08/05 - 20050271647 - Chimeric pro-caspases and methods of using same The present invention relates to a chimeric pro-caspase, which contains a pro-caspase domain and an oligomerizing domain. The invention also relates to an antibody that reacts specifically with a chimeric pro-caspase. In addition, the invention further relates to a polynucleotide encoding a chimeric pro-caspase, and to nucleotide sequences, which can ... 12/08/05 - 20050271646 - Fibrin material and method for producing and using the same This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops a tight structure with thin fibers and small pore size suitable for use as an anti-adhesion barrier. ... 11/24/05 - 20050260188 - Cross-linked gels of chemically activated carboxypolysaccharides and polyalkylene oxides Carboxypolysaccharides (CPS) including carboxymethyl cellulose and their derivatives are provided that can be made into sponges, gels, membranes, particulates and other forms, for a variety of antiadhesion, antithrombogenic, drug delivery and/or hemostatic applications during surgery and pharmacological therapeutics. CPSs derivatized with primary amines can be used alone or in combination ... 11/17/05 - 20050255097 - Modified venom and venom components as anti-retroviral agents The present invention relates to a class of proteins, a process of production thereof, and a method for treatment of neurological and viral diseases in humans and animals. More specifically it applies to the treatment of heretofore intractable diseases such as retro-viral infections including human immunodeficiency virus (HIV), simian immunodeficiency ... 11/17/05 - 20050255096 - Combination treatment for acute myocardial infarction A combination therapy for the treatment of acute myocardial infarction comprises administering a combination of a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof to a patient. The combination synergistically reduces mortality of patients with acute myocardial infarction. ... 11/03/05 - 20050244401 - Compositions and methods for reducing lung volume The invention includes methods for performing non-surgical lung volume reduction in a patient by (a) administering, through the patient's trachea, a composition comprising an enzyme (e.g., a protease, such as a serine protease (e.g., trypsin, chymotrypsin, elastase, or an MMP), and/or a detergent, and/or a polycation; and (b) collapsing a ... 10/20/05 - 20050232914 - Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof Methods and compositions for treating a wide range of inflammatory diseases and disorders, and for inhibiting selectin-mediated binding by administering a mocarhagin protein, or fragments thereof with mocarhagin protein activity are provided. The mocarhagin protein may be administered alone, or in combination with a cytokine, lymphokine, or hematopoietic factor. ... 10/06/05 - 20050220782 - Method of treatment for stroke employing administration of defibrinogenating agents to achieve a specific defibrinogenation pattern The present invention provides a method for the treatment of acute ischemic stroke based on a specific rate and pattern of defibrinogenation and subsequent refibrogenation associated with optimized efficacy and significantly improved safety. The administration of a single dose of defibrinogenating agent to achieve an optimal rate of defirinogenation avoids ... 09/29/05 - 20050214277 - Suspension comprising fibrinogen, thrombin and alcohol, a method for preparing such a suspension, a method for coating a carrier with such a suspension, a method of drying a coating of a carrier, and a coated collagen sponge A suspension of fibrinogen, thrombin, alcohol and optionally aprotinin is obtained by mixing fibrinogen in alcohol with thrombin in alcohol. The suspension contains fibrinogen and thrombin particles with a Folk Ward mean diameter of 25-100 μm. The thrombin may be human, bovine or recombinant. The fibrinogen may be human or ... 09/15/05 - 20050202002 - Protease for activating clotting factor vii A protease for activating the blood clotting factor VII is described, which (a) is inhibited by the presence of aprotinin, (b) is increased in its activity by calcium ions and/or heparin or heparin-related substances, and (c) in SDS-PAGE, on subsequent staining in the non-reduced state, has one or more brands ... 09/15/05 - 20050202001 - Enhancement of human epidermal melanogenesis The invention provides methods and compositions that promote sunless tanning in human skin using a MAPK path-way inhibitor, particularly, a MEK-inhibitor, which induces melanogenesis in epidermal melanocytes alone or in combination with a cAMP-elevating agent. The compositions are preferably administered topically to the skin. ... 09/15/05 - 20050202000 - Novel remombinant staphylokinase derivant and its preparation method and application thereof The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of thrombolytics and anticoagulant. Based on the line, structural analysis of the monomer and dimer of recombinant ... 09/08/05 - 20050196393 - Enhanced production of blood clotting factors and fibrin fabric The blood collection, processing and transfer by separation of discrete components containing additional citrate (at least about trisodium citrate 9% w/v) in one or other of collection or processing bag provides for enhanced yield and purity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and ... 08/25/05 - 20050186198 - Serine protease inhibitors Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders. ... 08/04/05 - 20050169908 - Use of aerosolized antithrombin to treat acute lung injury The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III through pulmonary delivery. ... 07/21/05 - 20050158301 - Thrombin peptide derivatives Disclosed are thrombin peptide derivatives comprising a polypeptide having the amino acid sequence SEQ ID NO. 2: Arg-Gly-Asp-Ala-Xaa-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val, or a C-terminal truncated fragment of the polypeptide having at least six amino acids. Xaa is alanine, glycine, serine, or an S-protected cysteine. Zero, one, two, or three amino acids in the ... 07/14/05 - 20050152889 - Biological boadhesive compositions and methods of preparation and use The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the ... 07/07/05 - 20050147600 - Angiotensin converting enzyme homolog and uses therefor The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying ... 06/30/05 - 20050142130 - Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima Described is a method for preventing and/or reducing the formation of neointima comprising delivering to cells of an individual angiotensin-(1-7) or a functional part, derivative and/or analogue thereof, wherein use is made of a delivery vehicle that includes means for releasing angiotensin-(1-7) or a functional part, derivative and/or analogue thereof. ... 06/30/05 - 20050142129 - Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor The present invention provides methods of using a blood clotting inhibitor to reduce post-surgical morbidity and mortality. In particular, perioperative use of a blood clotting inhibitor decreases surgical complications without significant adverse effects and is cost effective. ... 06/23/05 - 20050136046 - Methods of using therapeutic fibrinogen compositions A therapeutic composition effective on contact with thrombin at a site of treatment in a patient as a tissue adhesive, hemostat or sealant, said composition comprising non-autologous, non-single donor mammalian fibrinogen that is capable of polymerizing when provided in solution at said site at a concentration of about 30 mg/ml ... 06/02/05 - 20050118160 - Anticoagulant fusion protein anchored to cell membrane The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom ... ### FreshPatents.com Support |